ABRAXANE® for Advanced Non-Small Cell Lung Cancer | for HCPs
Phase II study of carboplatin/nab-paclitaxel/atezolizumab combination therapy for advanced nonsquamous non–small cell lung cancer patients with impaired renal function: RESTART trial | BMC Cancer | Full Text
Erstlinientherapie beim fortgeschrittenem NSCLC: Nab-Paclitaxel - das innovative und effektivere Taxan
New Clinical Trial Shows Promise in Treating Non-Small Cell Lung Cancer ( NSCLC)
Study schematics of ongoing Phase iii trials of atezolizumab in... | Download Scientific Diagram
Nab-paclitaxel nel NSCLC avanzato - ppt download
Treatment exposure in patients $70 years with squamous nsclc | Download Table
Phase 3 Trial Comparing Nanoparticle Albumin-Bound Paclitaxel With Docetaxel for Previously Treated Advanced NSCLC - ScienceDirect
Efficacy and safety of carboplatin with nab-paclitaxel versus docetaxel in older patients with squamous non-small-cell lung cancer (CAPITAL): a randomised, multicentre, open-label, phase 3 trial - The Lancet Healthy Longevity
Longer OS with atezolizumab + carboplatin + nab-paclitaxel in advanced squamous NSCLC - Medical Conferences
Atezolizumab plus carboplatin and nab‐paclitaxel versus carboplatin and nab‐ paclitaxel as treatments for Chinese, treatment‐naïve, stage IV, non‐squamous, non‐small‐cell lung cancer patients: A retrospective analysis - Chen - 2022 - Pharmacology Research &
NSCLC | NSCLC: Patienten profitieren von nab-Paclitaxel auch in der Erhaltungstherapie | springermedizin.de
Study flow diagram: patients with squamous cell non-small cell lung... | Download Scientific Diagram
A Phase I/II Study of Necitumumab Plus Pembrolizumab, Nab-Paclitaxel, and Carboplatin for Previously Untreated Advanced Squamous Non–Small Cell Lung Cancer Study: (NEJ048A/NEXUS) - ScienceDirect
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 ...
Treatment Rationale and Design for J‐SONIC: A Randomized Study of Carboplatin Plus Nab‐paclitaxel With or Without Nintedanib for Advanced Non–Small‐cell Lung Cancer With Idiopathic Pulmonary Fibrosis | Semantic Scholar
Carboplatin and nab-paclitaxel chemotherapy with or without atezolizumab as front-line management for treatment-naïve metastatic nonsquamous non-small cell lung cancer with PD-L1 staining: a retrospective study | Journal of Cancer Research and Clinical
Phase 3 Trial Comparing Nanoparticle Albumin-Bound Paclitaxel With Docetaxel for Previously Treated Advanced NSCLC - ScienceDirect
J-AXEL: nab-paclitaxel at least equal to docetaxel in pretreated NSCLC - memoinOncology
A Dose Finding Study of Weekly and Every-3-Week nab-Paclitaxel Followed by Carboplatin as First-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer - ScienceDirect
Nab-Paclitaxel in combination with Cisplatin Versus Docetaxel Plus Cisplatin as First-Line Therapy in Non-small Cell Lung Cancer | Scientific Reports
Biomedicines | Free Full-Text | Nab-Paclitaxel in the Treatment of Gastrointestinal Cancers—Improvements in Clinical Efficacy and Safety
A) Os and (B) PFs in patients $70 years with squamous nsclc.... | Download Scientific Diagram
Frontiers | Consolidation With Pembrolizumab and Nab-Paclitaxel After Induction Platinum-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer
nab-Paclitaxel + Carboplatin bei fortgeschrittenem NSCLC (kartoniertes Buch) | Schwäbischer Albverein e.V.
a) Progression-free survival (PFS) and (b) overall survival (OS)... | Download Scientific Diagram
IMpower131: Final OS Results of Carboplatin + Nab-Paclitaxel ± Atezolizumab in Advanced Squamous NSCLC on Vimeo
